Prospective Cohort With Clinic-biologic Database of Patients Treated by Immunotherapy
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- The protocol lists: ImmuCCo Cohort.
- Who it may be relevant to
- Registry conditions: Solid Tumor, Adult. Basic parameters: from 18 years · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- France
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Overview
ImmuCCo-1905 is a monocentric interventional study on patients treated by immunotherapy, which consist in establishment of a prospective clinic-biologic database over 5 years, associated with a biobank. This database will allow carrying out works aiming at assessing immunotherapy in real life situation.
Detailed description
The aim of this study is to establish a prospective clinic-biologic database of patients treated by immunotherapy. This database will allowed to carry out works (such as translational research) aiming at assessing immunotherapy in real life situation.
Other objectives of the study include:
* Describe overall survival, progression-free survival, response to immunotherapy (in particular hyper-progression, pseudo-progression) considering the first tumor assessment and the best response, prolonged response * Identifying prognostic factors of overall survival, progression-free survival, hyper-progression, best response under immunotherapy * Describe AEs (Adverse Events) potentially associated with immunotherapy, their kinetics of appearance, from the start of treatment and after the end of treatment in order to assess the risk of delayed appearance * To identify factors associated with increased risk of severe adverse event (grade \> 2 or leading to end of treatment) potentially related to immunotherapy, from the beginning of immunotherapy to 1 year after this start of the treatment, in patients who received at least 4 doses or who stopped the treatment earlier (before 4 doses) due to toxicity. * Identifying delayed adverse events potentially related to immunotherapy, occurring between 90 days and 1 year after the treatment discontinuation, in patients who received at least 4 doses or who stopped the treatment earlier (before 4 doses) due to toxicity. * To identify and describe rare toxicities * To evaluate the association between co-medications and disease evolution * To evaluate the association between co-medications and toxicities occurrence
Translational research objectives:
* To identify biomarkers that might be associated with tumor response and/or toxicity of immunotherapy from:
* Establishment of serum and plasma bank which will be used for diverse works; * A systematic analysis of the lymphocyte profile * To study the impact of tabagism on efficacy and toxicity of immunotherapy from systematic collection of urinary cotinine.
Interventions
- Other ImmuCCo Cohort
Blood sampling at initiation of immunotherapy, at the first tumor assessment, in case of severe toxicity. Urine collection at initiation of immunotherapy.
Primary outcome measures
- Number of patients treated by immunotherapy and registered in the database. [Time frame: 5 years]
Secondary outcome measures (5)
- Overall Survival [Time frame: 6 years]
- Progression-Free Survival [Time frame: 6 years]
- Tumor response [Time frame: 6 years]
- Co-medications [Time frame: 6 years]
- Toxicity of immunotherapy [Time frame: 6 years]
Eligibility criteria
Inclusion criteria
- Age ≥ 18 years
- Beginning a first immunotherapy by immune checkpoint inhibitor - anti-PD1 (Programmed cell Death protein-1), anti-PDL1 (Programmed cell Death protein-1 ligand), anti-CTLA4 (Cytotoxic T-Lymphocyte associated protein 4), as monotherapy or in combination, in the Centre Oscar Lambret (COL)
- In neo-adjuvant, adjuvant, recurrence or metastatic situation
- Suffering from solid tumor histologically documented
- Signed written informed consent
- Patient covered by the French " "Social Security" regime If the patient is already enrolled in clinical trial involving immunotherapy, the agreement of the sponsor of this new trial will be sought before his/her inclusion.
Exclusion criteria
- Pregnant or breastfeeding women
- Patient already treated by immunotherapy by immune checkpoint inhibitor
- Person under guardianship
- Inability to comply with medical follow-up of the trial (geographical, social or psychic reasons)
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: No
Study design
- Allocation
- N/A
- Model
- Single group
- Masking
- Open label
- Primary purpose
- Treatment
Study locations
France · 1 center
- Centre Oscar Lambret — Lille
Identifiers
NCT: NCT05223608 · ImmuCCo-1905 · 2020-A00854-35